We also investigated the progression-free survival (PFS) of these groups in TCGA, and found that all grade and lower-grade glioma patients with high TRIP13 levels showed shorter PFS (Figure 2J,K), but this was not significant in GBM patients (Figure 2L). This evidence concerns the gene TRIP13 and glioma.